• Profile
Close

Efficacy and safety of sarilumab for the treatment of posterior segment noninfectious uveitis (SARIL-NIU): The phase 2 SATURN study

Ophthalmology Feb 27, 2019

Heissigerova J, et al. - Researchers analyzed 58 candidates to analyze the effectiveness and safety of sarilumab (a human anti-interleukin-6 receptor antibody) to treat posterior segment noninfectious uveitis (NIU). They noticed a significant decline in the mean vitreous haze (VH) from baseline to week 16 with sarilumab vs placebo despite of assessment by the central reading center (−2.1 vs −1.7, respectively) or investigator (−2.5 vs −1.2) in the subgroup of eyes with VH grade ≥2 at baseline. They recorded a greater value of mean best-corrected visual acuity gain from baseline to week 16 with sarilumab vs placebo in the overall population (8.9 vs 3.6 letters, respectively) and in the subgroup of eyes with central subfield thickness (CST) ≥300 μm at baseline. They also found common ocular adverse events like worsening of uveitis and retinal infiltrates. Overall, they suggested subcutaneous sarilumab in the management of NIU of the posterior segment, especially in eyes with uveitic macular edema.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay